Cancer Medicine 2017; 6(7):1573--1580

Introduction {#cam41126-sec-0001}
============

Colorectal cancer is the third most commonly diagnosed cancer in males and the second in females, with an estimated 1.4 million new cases and 693,900 deaths occurring in 2012 [1](#cam41126-bib-0001){ref-type="ref"}. Complete resection is essential for achieving a cure. Although the resection rate has gradually increased, some patients still experience recurrence, even after curative surgery [2](#cam41126-bib-0002){ref-type="ref"}. Once recurrence has developed, the prognosis is poor. Therefore, it is important to identify reliable predictive factors for patients at high risk of recurrence.

Postoperative complications are observed in around 20% of patients who receive curative surgery with lymph node dissection for colorectal cancer [3](#cam41126-bib-0003){ref-type="ref"}, [4](#cam41126-bib-0004){ref-type="ref"}, [5](#cam41126-bib-0005){ref-type="ref"}, [6](#cam41126-bib-0006){ref-type="ref"}. Recent studies have shown that the postoperative complications were risk factors for the survival or disease recurrence in various types of malignancies [7](#cam41126-bib-0007){ref-type="ref"}, [8](#cam41126-bib-0008){ref-type="ref"}, [9](#cam41126-bib-0009){ref-type="ref"}, [10](#cam41126-bib-0010){ref-type="ref"}, [11](#cam41126-bib-0011){ref-type="ref"}, [12](#cam41126-bib-0012){ref-type="ref"}. Furthermore, some authors have shown that the immunological response against postoperative complications enhanced the viability of undetectable residual tumor cells after surgery, thereby increasing the risk of disease recurrence [13](#cam41126-bib-0013){ref-type="ref"}, [14](#cam41126-bib-0014){ref-type="ref"}. However, despite numerous studies performed in patients with various types of malignancies, most previous studies have used and evaluated retrospectively collected data with relatively small sample sizes of less than 200 from a single institution. Retrospective studies have many limitations, such as unspecified indications of surgery, heterogeneous populations, heterogeneous treatments, and description bias of surgical morbidity. Physicians can sometimes hesitate to perform postoperative chemotherapy in frail patients who easily develop surgical morbidity. Such frail patients might therefore have a particularly poor prognosis. To overcome such limitations associated with retrospective studies, we focused on cases that were enrolled in large randomized clinical trials of adjuvant chemotherapy by pooling individual patients' data. The impact of such morbidities on the prognosis must be reevaluated in a large cohort with prespecified indications of surgery, predefined treatments, and prospectively collected data from clinical trials.

The aim of this study was to determine whether or not the overall survival (OS) and disease‐free survival (DFS) were affected by the development of postoperative complications in patients who underwent curative resection for colorectal cancer by a pooled analysis of three large phase III studies performed in Japan. This study had the ultimate goal of evaluating and confirming the actual impact of surgical morbidity on the prognosis of colorectal cancer patients who received curative surgery.

Patients and Methods {#cam41126-sec-0002}
====================

Patients {#cam41126-sec-0003}
--------

The data and outcomes or patients enrolled in three phase III trials of Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) studies (7, 15, and 33) were pooled [15](#cam41126-bib-0015){ref-type="ref"}, [16](#cam41126-bib-0016){ref-type="ref"}, [17](#cam41126-bib-0017){ref-type="ref"}.

JFMC trials in the pooled analysis {#cam41126-sec-0004}
----------------------------------

### JFMC 7 and 15 {#cam41126-sec-0005}

These two randomized trials were relatively large‐scale trials conducted in Japan. They focused on the long‐term utilization of oral 5‐fluorouracil (FU) as adjuvant chemotherapy for colon or rectal cancer and compared the overall survival in the surgery‐alone arm with the treatment arms. The basic study designs of these trials were very similar, and included the following key eligibility criteria: stage of cancer macroscopic Dukes' B and C, age \<75 years, no severe complications, and follow‐up period 5 years. The main adjuvant chemotherapy was 1‐year administration of oral 5‐FUs (JFMC7‐1: 200 mg/day 5‐FU; JFMC7‐2 and JFMC15: 300 mg/day 1‐hexycarbamoyl‐5‐fluorouracil \[carmofur, HCFU\]). HCFU is an oral fluorinated pyrimidine developed as a 5‐FU lipophilic masked compound. All eligible patients were the target analysis set for the statistical analysis. There were 3394 patients enrolled in total for the JFMC 7 trial between February 1986 and December 1988 and 2315 enrolled in total in total for JFMC 15 trial between January 1989 and December 1990. The details of the protocol and primary analyses of JFMC 7 and JFMC 15 have been reported previously.

### JFMC 33 {#cam41126-sec-0006}

This phase III trial randomly assigned 1071 eligible patients from 2005 to 2007 at 233 centers to receive tegafur (UFT, 300 mg/m^2^/day as tegafur)/leucovorin (LV, 75 mg/day) for 28 of 35 days for 6 months in the control group or for 5 consecutive days per week for 18 months. Patients with curatively resected stage IIB/III colon cancer were eligible for enrollment in this trial. The primary endpoint was the overall survival. The details and primary analyses of JFMC 33 have been reported previously.

In this pooled analysis, the eligible patients were those who had stage I/II/III colorectal cancer and had received over D2 lymph node dissection. Thus, 754 and 496 patients were excluded from the intention‐to‐treat cohort of each study. In total, 5530 patients were included in the present study. Individual patient data were obtained and analyzed for the study.

Postoperative complications {#cam41126-sec-0007}
---------------------------

Each study prespecified that physicians must report any surgical morbidity at study enrollment. All information on complications was extracted from the case report forms of each trial. Major surgical complications were defined as follows: anastomotic leakage, pneumonia, bowel obstruction/ileus, surgical site infection, postoperative bleeding, urinary tract infection, and fistula. The patients were classified as those with postoperative complications (C group) and without postoperative complications (NC group).

Follow‐up {#cam41126-sec-0008}
---------

Patients were followed up in accordance with the protocol of each study. Briefly, during protocol treatment, the clinical findings and laboratory data were evaluated every 2 weeks. After completion of the protocol treatment, patients were followed up in accordance with a predefined surveillance schedule until recurrence or death was confirmed for 5 years after surgery. Recurrence was assessed based on computed tomography (CT) scans. These tests were carried out every 4 months during the first 2 years after surgery and once every 6 months from the third year onward.

Evaluations and statistical analyses {#cam41126-sec-0009}
------------------------------------

The background characteristics of the postoperative clinical and pathological parameters between the C and NC groups were compared using the Mann--Whitney test or chi‐square test. The OS was defined as the period between surgery and any cause of death. The DFS was defined as the period between surgery and the occurrence of recurrence, second cancer, or death, whichever came first. The data for patients who had not experienced an event were censored at the date of the final observation. The OS and DFS curves were calculated using the Kaplan--Meier method, and were compared by the log‐rank test. A Cox proportional hazards model was used to perform the univariate and multivariate survival analyses. In the multivariate analysis, adjuvant chemotherapy, age (\<60 or ≥60), gender, tumor diameter (\<50 or ≥50 mm), tumor location (colon or rectum), T status (T1 to T3 or T4), lymph node metastases (positive or negative), and lymphadenectomy (D2 or D3) were considered as available confounders based on a prior knowledge. Trials (JFMC7, 15, and 33) were also considered as a fixed effect in all multivariate Cox regression model. A *P* \< 0.05 (two‐sided) was defined as being statistically significant. SAS version 9.4 (SAS Institute, Inc., Cary, NC) was used for all statistical analyses. This study was approved by the ethical committee of the Japanese Foundation for Multidisciplinary Treatment of Cancer.

Results {#cam41126-sec-0010}
=======

Patients {#cam41126-sec-0011}
--------

The data of 5530 individual patients were evaluated in this study. The patients' ages ranged from 20 to 75 years (median: 60 years); 3104 patients were males and 2426 were females. The median follow‐up period was 5 years. Patients' demographics and clinical characteristics are summarized in Table ** ** [1](#cam41126-tbl-0001){ref-type="table-wrap"}. The age, gender, sex, tumor location, tumor diameter, UICC T status, and UICC N status were significantly different between the two groups. The incidence of rectal cancer tended to be higher in the C group than in the NC group.

###### 

A comparison of the clinicopathological factors between the patients with and without surgical complications

  Factors                  All cases (*n* = 5530)   C group (*n* = 861)   NC group (*n* = 4669)   *P*                        
  ------------------------ ------------------------ --------------------- ----------------------- ------ --------- --------- ---------
  Gender                                                                                                                     \<0.001
  Male                     3104                     56.1                  583                     67.7   2521      54.0      
  Female                   2426                     43.9                  278                     32.3   2148      46.0      
  Age (years)                                                                                                                \<0.001
  Median (range)           60 (20--75)              59 (27--75)           61 (20--75)                                        
  Tumor location                                                                                                   \<0.001   
  Colon                    4036                     73.0                  420                     48.8   3616      77.4      
  Rectal                   1492                     27.0                  441                     51.2   1051      22.5      
  Diameter of tumor (mm)                                                                                 0.002               
  Median (range)           50 (10--280)             50 (10--140)          50 (10--280)                                       
  Histology                                                                                                                  0.048
  Well‐mod                 5199                     94.0                  821                     95.4   4378      93.8      
  Poor                     136                      2.5                   11                      1.3    125       2.7       
  Others                   195                      3.5                   29                      3.4    166       3.6       
  UICC T status                                                                                                    \<0.001   
  T1--T3                   3767                     68.1                  536                     62.3   3231      69.2      
  T4                       1763                     31.9                  325                     37.7   1438      30.8      
  LN node metastases                                                                                     \<0.001             
  Negative                 3146                     56.9                  543                     63.1   2603      55.8      
  Positive                 2362                     42.7                  314                     36.5   2048      43.9      
  Missing                  22                       0.4                   4                       0.5    18        0.4       
  Lymph node dissection                                                                                            0.111     
  D2                       2293                     41.5                  378                     43.9   1915      41.0      
  D3                       3227                     58.4                  481                     55.9   2746      58.8      
  Missing                  10                       0.1                   2                       0.2    8         0.2       
  Adjuvant chemotherapy                                                                                  0.246               
  Yes                      3609                     65.3                  547                     63.5   3062      65.6      
  No                       1921                     34.7                  314                     36.5   1607      34.4      

Well‐mod, well to moderately differentiated; Poor, poorly differentiated; UICC, Union for International Cancer Control; LN, lymph node; C group, patients with surgical complications, NC group, patients without surgical complications.
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Surgical morbidity and mortality {#cam41126-sec-0012}
--------------------------------

Postoperative complications were found in 861 (15.6%) of the 5530 patients. The details of the complications are shown in Table [2](#cam41126-tbl-0002){ref-type="table-wrap"}. Bowel obstruction/ileus was the most frequently observed complication, followed by wound abscess and anastomotic leakage.

###### 

Details of postoperative complications

                            Number of patients   \%
  ------------------------- -------------------- -----
  Bowel obstruction/ileus   316                  5.7
  Surgical site infection   288                  5.2
  Anastomotic leakage       170                  3.1
  Urinary tract infection   119                  2.2
  Fistula                   47                   0.8
  Pneumonia                 42                   0.8
  Postoperative bleeding    38                   0.7

John Wiley & Sons, Ltd

Survival analysis {#cam41126-sec-0013}
-----------------

The OS rates at 3 and 5 years after surgery were 84.6% and 74.8% in the C group and 89.5% and 82.2% in the NC group, respectively; these values were significantly different between the two groups (*P* \< 0.0001). The OS curves are shown in Figure [1](#cam41126-fig-0001){ref-type="fig"}. In the univariate analysis, postoperative complication, gender, tumor diameter, tumor location, the T status, N status, lymphadenectomy, and use of adjuvant chemotherapy were all found to be significantly associated with the OS. The multivariate analysis showed that postoperative complications increased the risk of death by 31% (adjusted hazard ratio = 1.31; 95% confidence interval, 1.12--1.54; *P* = 0.001; Table [3](#cam41126-tbl-0003){ref-type="table-wrap"}).

![The overall survival curves of the C group (those with surgical complications) and NC group (those without surgical complications).](CAM4-6-1573-g001){#cam41126-fig-0001}

###### 

Univariate and multivariate Cox proportional hazards analyses of the clinicopathological factors for the disease‐free survival

  Factors                 Number   Univariate analysis   Multivariate analysis[a](#cam41126-note-0005){ref-type="fn"}                                       
  ----------------------- -------- --------------------- -------------------------------------------------------------- --------- ------------ ------------ ---------
  Surgical complication                                                                                                 \<0.001                             0.003
  No                      4669     1.00                                                                                           1.00                      
  Yes                     861      1.35                  1.18--1.55                                                               1.24         1.08--1.42   
  Age (years)                                                                                                           0.115                               0.093
  \<60                    2571     1.00                                                                                           1.00                      
  ≥60                     2959     1.09                  0.98--1.21                                                               1.10         0.99--1.22   
  Gender                                                                                                                0.001                               0.002
  Female                  2420     1.00                                                                                           1.00                      
  Male                    3104     1.24                  1.11--1.38                                                               1.19         1.07--1.33   
  Tumor diameter (mm)                                                                                                   0.041                               0.088
  \<50                    2423     1.00                                                                                           1.00                      
  ≥50                     3095     1.12                  1.01--1.25                                                               1.10         0.99--1.23   
  Tumor location                                                                                                        \<0.001                             \<0.001
  Colon                   4036     1.00                                                                                           1.00                      
  Rectal                  1492     1.48                  1.33--1.66                                                               1.37         1.21--1.55   
  UICC T status                                                                                                         \<0.001                             \<0.001
  T1--T3                  3767     1.00                                                                                           1.00                      
  T4                      1763     1.72                  1.54--1.91                                                     1.55      1.38--1.73                
  Lymph node metastases                                  \<0.001                                                                               \<0.001      
  Negative                3146     1.00                                                                                           1.00                      
  Positive                2362     2.15                  1.93--2.39                                                     2.38      2.12--2.66                
  Lymph node dissection                                  0.002                                                                                 0.001        
  D3                      3227     1.00                                                                                           1.00                      
  D2                      2293     1.18                  1.06--1.31                                                               1.19         1.07--1.33   
  Adjuvant chemotherapy                                  0.005                                                                                 0.023        
  No                      1921     1.00                                                                                           1.00                      
  Yes                     3609     0.84                  0.74--0.95                                                               0.87         0.77--0.98   

UICC, Union for International Cancer Control; HR, hazard ratio; CI, confidence interval.

The study was adjusted as a fixed effect in the multivariate Cox model.

John Wiley & Sons, Ltd

The DFS rates at 3 and 5 years after surgery were 75.6% and 68.9% in the C group patients and 80.2% and 75.8% in the NC group patients, respectively. The DFS was therefore significantly worse in the C group than in the NC group (*P* \< 0.001). The DFS curves are shown in Figure [2](#cam41126-fig-0002){ref-type="fig"}. In the univariate analysis, postoperative complication, gender, tumor diameter, tumor location, the T status, N status, lymphadenectomy, and use of adjuvant chemotherapy were found to be significantly associated with the DFS. The multivariate analysis showed that postoperative complications were significant independent risk factors for the DFS (Table [4](#cam41126-tbl-0004){ref-type="table-wrap"}). Adjusted hazard ratio for DFS was 1.24 (95% confidence interval, 1.08--1.42; *P* = 0.003).

![The disease‐free survival curves of the C group (those with surgical complications) and NC group (those without surgical complications).](CAM4-6-1573-g002){#cam41126-fig-0002}

###### 

Univariate and multivariate Cox proportional hazard analyses of the clinicopathological factors for the overall survival

  Factors                 Number   Univariate analysis   Multivariate analysis[a](#cam41126-note-0007){ref-type="fn"}                                       
  ----------------------- -------- --------------------- -------------------------------------------------------------- --------- ------------ ------------ ---------
  Surgical complication                                                                                                 \<0.001                             0.001
  No                      4669     1.00                                                                                           1.00                      
  Yes                     861      1.49                  1.28--1.73                                                               1.31         1.12--1.54   
  Age (years)                                                                                                           0.039                               0.003
  \<60                    2571     1.00                                                                                           1.00                      
  ≥60                     2959     1.14                  1.01--1.29                                                               1.21         1.07--1.37   
  Gender                                                                                                                0.289                               0.034
  Female                  2420     1.00                                                                                           1.00                      
  Male                    3104     1.23                  1.09--1.40                                                               1.15         1.01--1.30   
  Tumor diameter (mm)                                                                                                   \<0.001                             0.005
  \<50                    2423     1.00                                                                                           1.00                      
  ≥50                     3095     1.25                  1.11--1.42                                                               1.20         1.06--1.37   
  Tumor location                                                                                                        \<0.001                             0.001
  Colon                   4036     1.00                                                                                           1.00                      
  Rectal                  1492     1.56                  1.38--1.78                                                               1.27         1.11--1.47   
  UICC T status                                                                                                         \<0.001                             \<0.001
  T1--T3                  3767     1.00                                                                                           1.00                      
  T4                      1763     1.71                  1.52--1.94                                                     1.53      1.34--1.73                
  Lymph node metastases                                  \<0.001                                                                               \<0.001      
  Negative                3146     1.00                                                                                           1.00                      
  Positive                2362     1.98                  1.75--2.24                                                     2.48      2.17--2.83                
  Lymph node dissection                                  0.002                                                                                 0.007        
  D3                      3227     1.00                                                                                           1.00                      
  D2                      2293     1.22                  1.08--1.38                                                               1.19         1.05--1.35   
  Adjuvant chemotherapy                                  0.065                                                                                 0.231        
  No                      1921     1.00                                                                                           1.00                      
  Yes                     3609     0.90                  0.81--1.01                                                               0.92         0.80--1.06   

UICC, Union for International Cancer Control, HR, hazard ratio, CI, confidence interval.

The study was adjusted as a fixed effect in the multivariate Cox model.

John Wiley & Sons, Ltd

Subgroup analysis {#cam41126-sec-0014}
-----------------

The subgroup analyses were performed according to the type of treatment after surgery. The 5‐year OS rates in patients receiving adjuvant chemotherapy or surgery alone were 77.4% and 71.4% in the C group patients, respectively, and were 83.2% and 81.0% in the NC group patients, respectively (Fig. [S1](#cam41126-sup-0001){ref-type="supplementary-material"}). In patients randomized to surgery‐alone group, adjusted hazard ratio of postoperative complications for OS and DFS was 1.44 (95% confidence interval, 1.13--1.84) and 1.32 (95% confidence interval, 1.06--1.64), respectively. In patients randomized to the adjuvant chemotherapy group, adjusted hazard ratio of postoperative complications for OS and DFS was 1.23 (95% confidence interval, 1.00--1.52) and 1.19 (95% confidence interval, 0.99--1.43), respectively.

Impacts stratified by the site of the primary tumor were also examined. Crude Kaplan--Meier curves in colon cancer and rectum cancer were shown in Figure [S2](#cam41126-sup-0002){ref-type="supplementary-material"}. In colon cancer patients, adjusted hazard ratio of postoperative complications for OS and DFS was 1.30 (95% confidence interval, 1.03--1.64) and 1.28 (95% confidence interval, 1.05--1.57), respectively. In rectum cancer patients, adjusted hazard ratio of postoperative complications for OS and DFS was 1.31 (95% confidence interval, 1.05--1.63) and 1.19 (95% confidence interval, 0.98--1.44), respectively.

Discussion {#cam41126-sec-0015}
==========

This study examined whether or not postoperative complications were associated with a poorer OS and DFS after curative surgery for colorectal cancer in combined analyses of individual patients' data from the three large phase III studies evaluating the effects of adjuvant treatment. Our findings clearly indicated that postoperative complications were a significant independent risk factor for the OS and DFS. Similar trends were observed, regardless of the adjuvant treatment or tumor location.

The present study only included patients enrolled in phase III studies of adjuvant chemotherapy, meaning that all patients who had developed surgical morbidities had completely recovered from their complications before study entry and satisfied the eligibility criteria of each study. All patients were considered to be ready to receive adjuvant chemotherapy. Previous studies were associated with the major criticism that frail patients, who easily develop surgical complications, have a worse prognosis than nonfrail patients because of their frailty and not because of adjuvant chemotherapy. The present study clearly showed that surgical complications were associated with a worse prognosis, with no relation to the addition of adjuvant chemotherapy or type of adjuvant chemotherapy. This finding strongly suggested that the negative survival impact was due not to frail patients who did not receive adjuvant chemotherapy but to surgical morbidity itself.

In the present study, adjusted hazard ratio for OS was 1.31 (95% confidence interval, 1.12--1.54) and that for DFS was 1.24 (95% confidence interval, 1.08--1.42). Similar hazard ratio and 95% confidence interval were observed in the previous largest observational studies. Law et al. examined 1657 colorectal cancer patients [13](#cam41126-bib-0013){ref-type="ref"} and found that postoperative complications were an independent factor associated with a worse overall survival (hazard ratio of 1.26) and a higher rate of overall recurrence (hazard ratio of 1.26). Similar hazard ratios were also reported in other studies [18](#cam41126-bib-0018){ref-type="ref"}.

Although the present results are considered to be solid in terms of the study design and sample size, several limitations warrant mention. First, the patients in this cohort met the strict inclusion criteria of each clinical trial, which may have contained selection bias. When considering the generalizability, the impact of complications may be emphasized in this cohort. Second, there is a time bias in this study, as the data were collected over the relatively long period of 1986--2007. Surgical procedures and perioperative care might have changed over the years. Third, the definition and severity of morbidity were not strictly defined in each phase III study. The postoperative surgical complications were reported based not on the study protocol but on the judgment of individual physicians. Although the incidence of morbidity in this study was similar to that in other large studies [19](#cam41126-bib-0019){ref-type="ref"}, [20](#cam41126-bib-0020){ref-type="ref"}, some surgical complications might have been underestimated.

A further important limitation of all of the available data regarding postoperative complications, including the current study, is the lack of consensus regarding the appropriate cut‐off point and definition for evaluation of the postoperative complications. In this study, the definition and severity of the postoperative surgical complications were not determined in the three phase III studies. The postoperative surgical complications of this study were reported by the individual physicians, not based on a specific protocol. Although the incidence of the postoperative surgical complications was similar to other large phase III trials, some postoperative surgical complications might be underestimated. This would also greatly aid the use of the postoperative complications as stratification factor in future clinical trials.

In conclusion, this study confirmed that the development of postoperative complications was a risk factor for the overall survival and disease recurrence in patients who underwent curative surgery for colorectal cancer. Surgical morbidity must be considered as a stratification factor in future phase III trials evaluating the effects of adjuvant chemotherapy for colorectal cancer.
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###### 

**Figure S1.** The overall survival curves of the C group (those with surgical complications) and NC group (those without surgical complications) according to the type of treatment after surgery.

###### 

Click here for additional data file.

###### 

**Figure S2.** The overall survival curves of the C group (those with surgical complications) and NC group (those without surgical complications) according to the primary tumor location.

###### 

Click here for additional data file.
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